Business context and reporting period
This Form 10-Q covers the three months ended March 31, 2016. The registrant is Pieris Pharmaceuticals, Inc. (the request metadata names Palvella Therapeutics, Inc.). Pieris is a clinical-stage biopharmaceutical company developing Anticalin-based drug candidates. It had no product-sale revenue; reported revenue came from collaborations and grants.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 / prior date |
|---|---|---|
| Revenue | $1.247 million | $0.218 million |
| Research and development expense | $3.659 million | $1.525 million |
| General and administrative expense | $1.968 million | $2.394 million |
| Net loss | $4.161 million | $3.705 million |
| Basic and diluted loss per share | $0.10 | $0.13 |
| Cash and cash equivalents | $31.189 million at March 31, 2016 | $29.349 million at December 31, 2015 |
| Total liabilities | $10.029 million at March 31, 2016 | $2.822 million at December 31, 2015 |
Revenue increased 472%, mainly from Roche collaboration revenue: $0.837 million recognized from the upfront payment and $0.410 million for research services. The prior-year quarter included $0.218 million of government grants. Operating expenses rose 44%; R&D grew 140%, while G&A declined 18%. The filing reports no product sales, so product gross margins are not applicable.
Operating cash flow was positive $2.027 million, versus cash use of $3.593 million a year earlier. The 2016 inflow was substantially supported by $5.839 million in deferred revenue, including Roche upfront funding, and should not be read as recurring operating cash generation. Investing cash use was $0.068 million; there was no financing cash flow. The company reported no debt balance at March 31, 2016 and no interest expense for the quarter. Cash increased by $1.839 million, including the effect of foreign exchange.
Material changes and business developments
- R&D spending increased by $2.134 million, reflecting increased work on PRS-060 and the 300-series, personnel and other R&D costs; spending on PRS-080 declined following completion of its Phase Ia trial.
- G&A declined by $0.426 million, primarily due to lower legal, consulting and audit costs.
- Accumulated deficit was $84.027 million. Stockholders’ equity decreased to $27.176 million from $31.128 million at year-end 2015.
- After quarter-end, on April 18, 2016, Pieris entered a non-exclusive license agreement with Enumeral. It agreed to pay a $250,000 upfront fee and a $750,000 maintenance fee due May 31, 2016, plus potential development and sales milestones of up to $37.8 million and $67.5 million, respectively, and royalties. An optional antibody license would involve an additional undisclosed upfront payment and further potential obligations.
Outlook, commentary and risks
Management expected existing cash to fund operations and capital expenditure requirements for at least the next 12 months, but anticipated substantial losses and increasing cash needs for several years and said additional funding would be required to continue its plans. Future financing may be unavailable or unfavorable and could dilute shareholders, impose debt covenants, or require surrendering valuable rights.
- For the 300-series, Pieris expected to complete preclinical work in 2016; it targeted completion of PRS-343 IND-enabling studies and the start of a Phase I study in 2017.
- For PRS-080, the company expected to complete its Phase Ib study in CKD5 patients requiring hemodialysis by the end of 2016.
- For PRS-060, it was preparing process optimization, manufacturing and preclinical safety work, with a Phase I trial intended for 2017.
- Revenue is expected to remain dependent on collaboration upfront payments, research funding and milestones; timing and amounts are uncertain. The company warned that development, clinical, regulatory, manufacturing, financing, intellectual-property and foreign-exchange risks could materially affect results.
- The filing states that risk factors were not materially changed from the 2015 Form 10-K. Management reported effective internal control over financial reporting and disclosure controls as of March 31, 2016. It reported no off-balance-sheet arrangements and no material changes in internal controls.
Important facts for investors to verify
- Confirm the identity discrepancy: this filing is for Pieris Pharmaceuticals, Inc., not Palvella Therapeutics, Inc.
- Assess the cash runway against forecast clinical, manufacturing and operating costs, and the company’s stated need for future funding.
- Distinguish cash receipts and deferred collaboration revenue from revenue earned during the period; review the Roche agreement’s performance obligations and potential milestone conditions.
- Review the Enumeral agreement’s near-term payment dates, optional license terms, milestones and royalties.
- Verify the Roche milestone disclosure: the filing states potential milestones of approximately $423.9 million, while its listed development/regulatory and sales categories total $418.6 million; the filing text does not explain the difference.